Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSTL NYSE:PACS NASDAQ:PGNY NASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSTLCastle Biosciences$14.65-3.3%$18.01$14.61▼$35.84$437.42M1.09357,460 shs421,590 shsPACSPACS Group$10.62-4.0%$11.71$8.28▼$43.92$1.69B0.88488,840 shs625,371 shsPGNYProgyny$22.49-4.3%$22.11$13.39▼$27.15$2.02B1.321.01 million shs1.21 million shsVCYTVeracyte$23.64+0.6%$26.23$19.73▼$47.32$1.84B1.971.97 million shs1.74 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSTLCastle Biosciences-3.30%-8.84%-26.79%-24.29%-39.29%PACSPACS Group-3.63%-9.23%-18.75%+5.25%-70.29%PGNYProgyny-4.34%-2.68%+5.89%-3.19%-20.25%VCYTVeracyte+0.55%-6.38%-14.29%-22.11%-1.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCSTLCastle Biosciences3.0325 of 5 stars3.55.00.00.01.71.70.6PACSPACS Group3.1189 of 5 stars3.43.00.00.01.40.01.9PGNYProgyny2.0323 of 5 stars2.31.00.00.03.52.51.3VCYTVeracyte2.9116 of 5 stars3.40.00.04.34.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSTLCastle Biosciences 3.00Buy$37.00152.56% UpsidePACSPACS Group 2.86Moderate Buy$34.29222.84% UpsidePGNYProgyny 2.67Moderate Buy$24.8210.35% UpsideVCYTVeracyte 2.70Moderate Buy$40.9073.01% UpsideCurrent Analyst Ratings BreakdownLatest CSTL, PGNY, VCYT, and PACS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025PGNYProgynyTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$24.00 ➝ $27.007/8/2025PGNYProgynyLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/8/2025PGNYProgynyLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$28.005/21/2025CSTLCastle BiosciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$44.00 ➝ $40.005/12/2025PGNYProgynyCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$23.00 ➝ $21.005/8/2025VCYTVeracyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $42.005/8/2025VCYTVeracyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $41.005/6/2025CSTLCastle BiosciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $35.005/6/2025CSTLCastle BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $37.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSTLCastle Biosciences$332.07M1.27$0.95 per share15.40$16.28 per share0.90PACSPACS Group$3.11B0.52N/AN/AN/A∞PGNYProgyny$1.17B1.65$0.33 per share68.13$4.96 per share4.53VCYTVeracyte$445.76M4.15$1.04 per share22.67$15.17 per share1.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSTLCastle Biosciences$18.25M-$0.19N/AN/AN/A-1.46%3.41%2.95%8/4/2025 (Estimated)PACSPACS Group$112.87MN/A0.005.97N/AN/AN/AN/A8/11/2025 (Estimated)PGNYProgyny$54.34M$0.5739.4634.602.364.33%10.90%7.20%8/7/2025 (Estimated)VCYTVeracyte$24.14M$0.4157.6632.83N/A7.13%6.14%5.60%8/6/2025 (Estimated)Latest CSTL, PGNY, VCYT, and PACS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025PACSPACS Group$0.45N/AN/AN/AN/AN/A8/7/2025Q2 2025PGNYProgyny$0.42N/AN/AN/A$315.70 millionN/A8/6/2025Q2 2025VCYTVeracyte$0.31N/AN/AN/A$120.90 millionN/A8/4/2025Q2 2025CSTLCastle Biosciences-$0.44N/AN/AN/A$71.53 millionN/A5/8/2025Q1 2025PGNYProgyny$0.45$0.17-$0.28$0.17$307.86 million$324.04 million5/5/2025Q1 2025CSTLCastle Biosciences-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCSTLCastle BiosciencesN/AN/AN/AN/AN/APACSPACS GroupN/AN/AN/AN/AN/APGNYProgynyN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSTLCastle Biosciences0.029.379.19PACSPACS GroupN/AN/AN/APGNYProgynyN/A2.392.39VCYTVeracyteN/A5.104.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSTLCastle Biosciences92.60%PACSPACS GroupN/APGNYProgyny94.93%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipCSTLCastle Biosciences6.50%PACSPACS GroupN/APGNYProgyny9.40%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSTLCastle Biosciences54028.87 million27.00 millionOptionablePACSPACS Group32,433152.40 millionN/AOptionablePGNYProgyny31085.72 million77.66 millionOptionableVCYTVeracyte79078.32 million77.22 millionOptionableCSTL, PGNY, VCYT, and PACS HeadlinesRecent News About These CompaniesGSA Capital Partners LLP Takes Position in Veracyte, Inc. (NASDAQ:VCYT)August 1 at 5:40 AM | marketbeat.comPicton Mahoney Asset Management Has $7.72 Million Stake in Veracyte, Inc. (NASDAQ:VCYT)July 30 at 4:51 AM | marketbeat.comVeracyte (VCYT) to Release Quarterly Earnings on WednesdayJuly 30 at 4:33 AM | marketbeat.comVictory Capital Management Inc. Purchases 41,248 Shares of Veracyte, Inc. (NASDAQ:VCYT)July 29, 2025 | marketbeat.comVeracyte (VCYT) Soars 7.0%: Is Further Upside Left in the Stock?July 28, 2025 | zacks.comUniversal Beteiligungs und Servicegesellschaft mbH Purchases 22,074 Shares of Veracyte, Inc. (NASDAQ:VCYT)July 28, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Stake Lessened by ARK Investment Management LLCJuly 27, 2025 | marketbeat.comNikko Asset Management Americas Inc. Cuts Stock Position in Veracyte, Inc. (NASDAQ:VCYT)July 27, 2025 | marketbeat.comPinnacle Associates Ltd. Purchases New Stake in Veracyte, Inc. (NASDAQ:VCYT)July 27, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Shares Gap Up - What's Next?July 27, 2025 | americanbankingnews.comVeracyte (VCYT) Soars 7% on S&P SmallCap 600 InclusionJuly 26, 2025 | insidermonkey.comVeracyte (NASDAQ:VCYT) Shares Gap Up - Time to Buy?July 26, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Raised to Buy at Wall Street ZenJuly 26, 2025 | marketbeat.comVeracyte to replace Triumph in S&P SmallCap 600 indexJuly 25, 2025 | msn.comY Intercept Hong Kong Ltd Acquires 24,416 Shares of Veracyte, Inc. (NASDAQ:VCYT)July 24, 2025 | marketbeat.comGW&K Investment Management LLC Raises Stake in Veracyte, Inc. (NASDAQ:VCYT)July 22, 2025 | marketbeat.comJennison Associates LLC Buys 166,605 Shares of Veracyte, Inc. (NASDAQ:VCYT)July 20, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Trading Down 5.9% - Here's WhyJuly 19, 2025 | marketbeat.comRep. Gilbert Ray Cisneros, Jr. Purchases Shares of Veracyte, Inc. (NASDAQ:VCYT)July 19, 2025 | marketbeat.comVeracyte Inc (VCYT) Stock Price Down 4.21% on Jul 18July 18, 2025 | gurufocus.comVeracyte, Inc. (NASDAQ:VCYT) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCSTL, PGNY, VCYT, and PACS Company DescriptionsCastle Biosciences NASDAQ:CSTL$14.65 -0.50 (-3.30%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$15.58 +0.93 (+6.34%) As of 08/1/2025 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.PACS Group NYSE:PACS$10.62 -0.44 (-3.98%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$10.62 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.Progyny NASDAQ:PGNY$22.49 -1.02 (-4.34%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$22.24 -0.25 (-1.11%) As of 08/1/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.Veracyte NASDAQ:VCYT$23.64 +0.13 (+0.55%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$23.66 +0.02 (+0.09%) As of 08/1/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
